TW202304415A - 含有細菌的藥物製劑 - Google Patents

含有細菌的藥物製劑 Download PDF

Info

Publication number
TW202304415A
TW202304415A TW111113512A TW111113512A TW202304415A TW 202304415 A TW202304415 A TW 202304415A TW 111113512 A TW111113512 A TW 111113512A TW 111113512 A TW111113512 A TW 111113512A TW 202304415 A TW202304415 A TW 202304415A
Authority
TW
Taiwan
Prior art keywords
bacteria
cryoprotectant
pharmaceutical formulation
weight
bacterium
Prior art date
Application number
TW111113512A
Other languages
English (en)
Chinese (zh)
Inventor
梅荷達利亞 雅西奇
柯林 麥肯納
Original Assignee
美商艾弗洛生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾弗洛生物科技股份有限公司 filed Critical 美商艾弗洛生物科技股份有限公司
Publication of TW202304415A publication Critical patent/TW202304415A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111113512A 2021-04-08 2022-04-08 含有細菌的藥物製劑 TW202304415A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163172370P 2021-04-08 2021-04-08
US63/172,370 2021-04-08
US202163197000P 2021-06-04 2021-06-04
US63/197,000 2021-06-04

Publications (1)

Publication Number Publication Date
TW202304415A true TW202304415A (zh) 2023-02-01

Family

ID=81581166

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111113512A TW202304415A (zh) 2021-04-08 2022-04-08 含有細菌的藥物製劑

Country Status (6)

Country Link
US (1) US20250073285A1 (enExample)
EP (1) EP4319723A1 (enExample)
JP (1) JP2024516110A (enExample)
KR (1) KR20240006543A (enExample)
TW (1) TW202304415A (enExample)
WO (1) WO2022217030A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102263A1 (en) * 2018-06-07 2019-12-12 Artugen Therapeutics Ltd. Methods and compositions for the treatment of c. difficile

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5292522A (en) 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
CA2543172A1 (en) 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
ES2425385T3 (es) * 2009-04-30 2013-10-15 Actogenix N.V. Crioprotectores para la liofilización de las bacterias de ácido láctico
CN105142616B (zh) 2013-03-01 2018-02-13 Bpsi控股有限责任公司 含有硅酸钙的延迟释放薄膜包衣及其包被的底物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
KR102563191B1 (ko) * 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
GB2564481B (en) * 2017-07-14 2019-10-23 4D Pharma Leon S L U Process
US11090341B2 (en) * 2018-02-06 2021-08-17 Evelo Biosciences, Inc. Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
US20210205378A1 (en) * 2018-05-31 2021-07-08 Hokukon Co., Ltd. Lactic acid bacteria and use thereof
CA3102263A1 (en) 2018-06-07 2019-12-12 Artugen Therapeutics Ltd. Methods and compositions for the treatment of c. difficile
WO2020120714A1 (en) 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
IT201900006056A1 (it) * 2019-04-18 2020-10-18 Probiotical Spa Procedimento per la preparazione di una biomassa di cellule di batteri liofilizzate stabili e determinazione della loro stabilità mediante un metodo citofluorimetrico
CA3143994A1 (en) * 2019-06-21 2020-12-24 Evelo Biosciences, Inc. Compositions and methods of treating a th2-mediated condition using prevotella
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp

Also Published As

Publication number Publication date
WO2022217030A1 (en) 2022-10-13
US20250073285A1 (en) 2025-03-06
JP2024516110A (ja) 2024-04-12
EP4319723A1 (en) 2024-02-14
KR20240006543A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
US20220211773A1 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
US10702561B2 (en) Pharmaceutical compositions comprising a Blautia strain
US11090341B2 (en) Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
TW202140051A (zh) 具有改善的崩散譜之固體劑型
TW202114718A (zh) 經加工的微生物胞外囊泡
TW202135783A (zh) 包含細菌和微生物胞外囊泡之固體劑型
CN115551486A (zh) 具有改善的崩解谱的固体剂型
TW202228653A (zh) 細菌之固體劑型
TW202304486A (zh) 福涅拉氏菌屬細胞外囊泡製劑
TW202237155A (zh) 細胞外囊泡製劑
TW202302125A (zh) 固體劑型
TW202216178A (zh) 使用巨型球菌屬物種治療疾病及障礙之組成物及方法
WO2023114296A2 (en) Extracellular vesicle preparations
US20250073285A1 (en) Pharmaceutical composition containing bacteria
TW202322787A (zh) 包含細菌和微生物胞外囊泡之固體劑型
CN117615748A (zh) 含有细菌的药物组合物
CN116867502A (zh) 细菌的固体剂型